Literature DB >> 2668776

[Botulinum toxin in therapy of craniocervical dystonia].

D Dressler1, R Benecke, B Conrad.   

Abstract

Craniocervical dystonias are a major therapeutic problem, since in the majority of cases various drug regimens as well as surgical interventions either fail or are accompanied by serious side effects. Botulinum toxin, well known as a biological toxin which blocks the cholinergic neuromuscular synapse, proved to be a new and successful concept in the treatment of these disorders. In the present study, mechanisms of action, clinical indications and practical use of botulinum toxin are described.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2668776

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  9 in total

Review 1.  New approaches in the treatment of the dystonias.

Authors:  N Diederich; C G Goetz; C L Comella
Journal:  Klin Wochenschr       Date:  1990-10-03

2.  [Pharmacology of botulinum toxin drugs].

Authors:  D Dressler
Journal:  HNO       Date:  2012-06       Impact factor: 1.284

Review 3.  [Pharmacological aspects of therapeutic botulinum toxin preparations].

Authors:  D Dressler
Journal:  Nervenarzt       Date:  2006-08       Impact factor: 1.214

Review 4.  A brief history of neurological botulinum toxin therapy in Germany.

Authors:  Dirk Dressler; Peter Roggenkaemper
Journal:  J Neural Transm (Vienna)       Date:  2017-07-21       Impact factor: 3.575

5.  Botulinum toxin to suppress hyperkinesias after hypoglossal-facial nerve anastomosis.

Authors:  D Dressler; P W Schönle
Journal:  Eur Arch Otorhinolaryngol       Date:  1990       Impact factor: 2.503

6.  Local botulinum toxin in the treatment of spastic drop foot.

Authors:  R Dengler; U Neyer; K Wohlfarth; U Bettig; H H Janzik
Journal:  J Neurol       Date:  1992-08       Impact factor: 4.849

7.  Botulinum toxin treatment in patients with hemifacial spasm.

Authors:  R Laskawi; M Ellies; C Drobik; A Bätz
Journal:  Eur Arch Otorhinolaryngol       Date:  1994       Impact factor: 2.503

8.  [Muscle afferent block in the treatment of oromandibular dystonia. Difference in effect between masticatory and lingual muscles].

Authors:  K Yoshida
Journal:  Nervenarzt       Date:  2003-05-13       Impact factor: 1.214

9.  [Long-term therapy of focal dystonia and facial hemispasm with botulinum toxin A].

Authors:  T Vogt; F Lüssi; A Paul; P Urban
Journal:  Nervenarzt       Date:  2008-08       Impact factor: 1.214

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.